Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)

被引：1

作者：

Akyildiz, Arif ^{[1
]}

Guven, Deniz Can ^{[1
]}

Koksal, Baris ^{[1
]}

Karaoglan, Beliz Bahar ^{[2
]}

Kivrak, Derya ^{[3
]}

Ismayilov, Rashad ^{[4
]}

Aslan, Firat ^{[5
]}

Sutcuoglu, Osman ^{[6
]}

Yazici, Ozan ^{[6
]}

Kadioglu, Ahmet ^{[7
]}

Alan, Ozkan ^{[8
]}

Majidova, Nargiz ^{[9
]}

Erciyestepe, Mert ^{[10
]}

Ozcan, Erkan ^{[11
]}

Akdag, Goncagul ^{[12
]}

Taban, Hakan ^{[13
]}

Kaya, Ali Osman ^{[14
]}

Guliyev, Murad ^{[15
]}

Yildirim, Nilgun ^{[16
]}

Sakalar, Teoman ^{[17
]}

Yazilitas, Dogan ^{[18
]}

Unal, Caglar ^{[19
]}

On, Sercan ^{[20
]}

Biter, Sedat ^{[21
]}

Demirci, Nebi Serkan ^{[15
]}

Senler, Filiz Cay ^{[2
]}

Kemal, Yasemin ^{[22
]}

Halil, Omer Diker ^{[23
]}

Gullu, Ibrahim ^{[1
]}

Aksoy, Sercan ^{[1
]}

机构：

[1] Hacettepe Univ, Canc Inst, Dept Med Oncol, Ankara, Turkiye

[2] Ankara Univ, Fac Med, Dept Med Oncol, Ankara, Turkiye

[3] Univ Hlth Sci, Antalya Training & Res Hosp, Dept Med Oncol, Antalya, Turkiye

[4] Hacettepe Univ, Dept Internal Med, Sch Med, Ankara, Turkiye

[5] Ankara Med Pk Hosp, Dept Med Oncol, Ankara, Turkiye

[6] Gazi Univ, Fac Med, Dept Med Oncol, Ankara, Turkiye

[7] Dr Abdurrahman Yurtaslan Oncol Training & Res Hosp, Dept Med Oncol, Ankara, Turkiye

[8] Koc Univ, Dept Med Oncol, Istanbul, Turkiye

[9] Marmara Univ, Pendik Training & Res Hosp, Dept Med Oncol, Istanbul, Turkiye

[10] Prof Dr Cemil Tascioglu City Hosp, Dept Med Oncol, Istanbul, Turkiye

[11] Trakya Univ, Fac Med, Dept Med Oncol, Edirne, Turkiye

[12] Univ Hlth Sci, Kartal Dr Lutfi Kirdar City Hosp, Dept Med Oncol, Istanbul, Turkiye

[13] Samsun Training & Res Hosp, Dept Med Oncol, Samsun, Turkiye

[14] Biruni Univ, Fac Med, Dept Med Oncol, Istanbul, Turkiye

[15] Istanbul Univ Cerrahpasa, Cerrahpasa Sch Med, Dept Med Oncol, Istanbul, Turkiye

[16] Firat Univ, Med Fac, Dept Med Oncol, Elazig, Turkiye

[17] Necip Fazil City Hosp, Dept Med Oncol, Kahramanmaras, Turkiye

[18] Ankara Etlik City Hosp, Dept Med Oncol, Ankara, Turkiye

[19] Gayrettepe Florence Nightingale Hosp, Dept Med Oncol, Istanbul, Turkiye

[20] Ege Univ, Fac Med, Dept Oncol, Izmir, Turkiye

[21] Cukurova Univ, Fac Med, Dept Med Oncol, Adana, Turkiye

[22] Altinbas Univ, Fac Med, Dept Med Oncol, Samsun, Turkiye

[23] Near East Univ Hosp, Dept Med Oncol, Nicosia, Cyprus

来源：

EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY | 2024年 / 281卷 / 09期

关键词：

Head and neck cancer; Nivolumab; SQUAMOUS-CELL CARCINOMA;

D O I：

10.1007/s00405-024-08744-4

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

Objectives Head and neck cancers (HNCs) represent a significant global health concern due to high morbidity and mortality rates. Despite therapeutic advances, the prognosis for advanced or recurrent cases remains challenging. Nivolumab obtained approval for recurrent or metastatic HNC based on the Phase III CheckMate 141 trial. This study aimed to evaluate the real-world outcomes of nivolumab in patients with non-nasopharyngeal HNC. Design In this multicenter retrospective study, we analyzed 124 patients with recurrent or metastatic non-nasopharyngeal HNC who received nivolumab in the second-line setting and beyond. Data were collected from 20 different cancer centers across Turkey. The effectiveness and safety of the treatment and survival outcomes were evaluated. Results Nivolumab exhibited favorable clinical responses, yielding an objective response rate of 29.9% and a disease control rate of 55.7%. Safety assessments revealed a generally well-tolerated profile, with no instances of treatment discontinuation or mortality due to side effects. Survival analysis disclosed a median overall survival (OS) of 11.8 (95% CI 8.4-15.2) months. Multivariate analysis revealed that ECOG-PS >= 1 (HR: 1.64, p = 0.045), laryngeal location (HR: 0.531, p = 0.024), and neutrophil-to-lymphocyte ratio > 3.5 (HR: 1.97, p = 0.007) were independent predictors of OS. Conclusions Nivolumab is an effective and safe treatment option for patients with recurrent or metastatic non-nasopharyngeal HNC in real-world settings. Further studies are needed on factors affecting response to treatment and survival outcomes.

引用

页码：4991 / 4999

页数：9

共 50 条

[41] The PD-L1 protein expression in Chinese patients with recurrent or metastatic head and neck squamous cell carcinoma: A multi-center retrospective study
Lu, Haizhen
Kuang, Dong
Jiang, Lili
Yun, Jingping
Xia, Qingxin
Wang, Jian
Duan, Pei
Zhou, Ping
Zang, Shengbing
Jin, Yiping
Jiang, Xiangnan
Li, Jielin
Tang, Wenmin
Zhou, Jiansong
Chen, Jihua
Ying, Jianming
CANCER RESEARCH, 2023, 83 (07)
[42] HANNA - REAL-WORLD EVIDENCE FROM A GERMAN, PROSPECTIVE, NON-INTERVENTIONAL STUDY WITH NIVOLUMAB IN PATIENTS WITH RECURRENT/METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
von der Heyde, E.
Welslau, M.
Gauler, T.
Hahn, D.
Wittekindt, C.
Mueller-Huesmann, H.
Bockmuehl, U.
Mauz, P. S.
Waldenberger, D.
Dietz, A.
Singh, P.
VALUE IN HEALTH, 2019, 22 : S437 - S437
[43] Clinical outcomes and therapeutic modalities in older Chinese patients with MCL: a multi-center real-world retrospective study
Yang, Yuan
Yang, Ping
Zhang, Wei
Liu, Hui
Sun, Xiuhua
Xiao, Xiubin
Wang, Jingwen
Li, Zhenling
Li, Lihong
Wang, Shuye
He, Juan
Li, Xiaoling
Cai, Qingqing
Zhang, Weilong
Wang, Jing
Li, Chunyuan
Chen, Yingtong
Liu, Shuozi
Jing, Hongmei
ANNALS OF MEDICINE, 2025, 57 (01)
[44] Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients
Matsuki, Takashi
Okamoto, Isaku
Fushimi, Chihiro
Takahashi, Hideaki
Okada, Takuro
Kondo, Takahito
Sato, Hiroki
Ito, Tatsuya
Tokashiki, Kunihiko
Tsukahara, Kiyoaki
Hanyu, Kenji
Masubuchi, Tatsuo
Tada, Yuichiro
Miura, Kouki
Omura, Go
Sawabe, Michi
Kawakita, Daisuke
Yamashita, Taku
CANCERS, 2020, 12 (11) : 1 - 13
[45] Real-World data of triplet combination of trastuzumab, lapatinib and chemotherapy in HER2-positive metastatic breast cancer: A multi-center retrospective study
Li, Y.
Gong, C.
Lu, Q.
Zhou, Z.
Luo, T.
Li, W.
Li, G.
Ge, R.
Wang, B.
EUROPEAN JOURNAL OF CANCER, 2020, 138 : S66 - S66
[46] Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer Patients: A Retrospective, Multicenter Study
NAKANO, T. A. K. A. F. U. M., I
YASUMATSU, R. Y. U. J., I
HASHIMOTO, K. A. Z. U. K. I.
KUGA, R. Y. O. S. U. K. E.
HONGO, T. A. K. A. H. I. R. O.
YAMAMOTO, H. I. D. E. T. A. K. A.
MATSUO, M. I. O. K. O.
WAKASAKI, T. A. K. A. H. I. R. O.
JIROMARU, R. I. N. A.
MANAKO, T. O. M. O. M., I
TOH, S. A. T. O. S. H., I
MASUDA, M. U. N. E. Y. U. K., I
YAMAUCHI, M. O. R. I. Y. A. S. U.
KURATOMI, Y. U. I. C. H. I. R. O.
TAURA, M. A. S. A. H. I. K. O.
TAKEUCHI, T. O. R. A. N. O. S. H. I. N.
NAKAGAWA, T. A. K. A. S. H., I
ANTICANCER RESEARCH, 2022, 42 (07) : 3653 - 3664
[47] Real-world Data Study of the Efficacy and Toxicity of Nivolumab vs. Cetuximab and Predictors of Response to Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck in a European Population
Macia-Rivas, Lola
Fernandez-Laguna, Clara luz
Alvarez-Asteinza, Cristina
Maray, Ivan
Carbajales-Alvarez, Monica
Lozano-Blazquez, Ana
ANTICANCER RESEARCH, 2023, 43 (04) : 1681 - 1688
[48] Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study
Dulgar, Ozgecan
Turker, Sema
Basaran, Gul
Araz, Murat
Sumbul, Ahmet Taner
Caglayan, Dilek
Gumusay, Ozge
Biter, Sedat
Konca, Ahmet
Ozen, Mirac
Demir, Hacer
Ozdemir, Melek
Karatas, Fatih
Sahin, Elif
Cavdar, Eyyup
Yasin, Ayse Irem
Yasar, Alper
Derin, Suemeyra
Pehlivan, Metin
Uyeturk, Ummugul
Ozdemir, Ozlem
Kayikcioglu, Erkan
Ak, Naziye
Sakalar, Teoman
Sakin, Abdullah
Buyuksimsek, Mahmut
Ay, Seval
Erturk, Ismail
Akbas, Sinem
Yucel, Kadriye Bir
Gumus, Mahmut
JOURNAL OF CHEMOTHERAPY, 2024,
[49] Evaluation of gemcitabine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A Southwest Oncology Group Phase II study
Samlowski, WE
Gundacker, H
Kuebler, JP
Giguere, JK
Mills, GM
Schuller, DE
Ensley, JF
INVESTIGATIONAL NEW DRUGS, 2001, 19 (04) : 311 - 315
[50] Evaluation of Gemcitabine in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Southwest Oncology Group Phase II Study
Wolfram E. Samlowski
Holly Gundacker
J. Philip Kuebler
Jeffrey K. Giguere
Glenn M. Mills
David E. Schuller
John F. Ensley
Investigational New Drugs, 2001, 19 : 311 - 315

← 1 2 3 4 5 →